Access to DTP-Based Combination Vaccines in Asia-Pacific Countries between 2019 and 2022.

Access to DTP-Based Combination Vaccines in Asia-Pacific Countries between 2019 and 2022.

Publication date: Dec 28, 2023

The Asia-Pacific countries are highly diverse in health and economic conditions that may impact vaccine access and uptake. Our study aimed to characterize patterns of health access to DTP-based combination vaccines in 10 countries from 2019 to 2022 using the IQVIA-MIDAS database. The availability, affordability, and accessibility were compared across countries by national health and economic performance indicators using Spearman’s rank correlation coefficient. Our findings showed that the three aspects of access to DTP-based vaccines varied substantially in the Asia-Pacific region, with higher levels in countries with better health and economic performance. Affected by the COVID-19 pandemic, vaccine accessibility fluctuates significantly in lower-income countries, with DTP coverage rates falling by more than 14% in the Philippines and Indonesia between 2019 and 2021. For availability and affordability, Singapore and Malaysia from high-income groups were largely affected, which may be related to health expenditure as a percentage of gross domestic product (Coefficient = 0. 39, p = 0. 03). Our study indicates that greater attention needs to be paid to national health expenditure and routine immunization services to improve vaccine disparities and increase the robustness and resilience of the vaccine supply chain during public health emergencies.

Open Access PDF

Concepts Keywords
Affordability Asia-Pacific
Covid COVID-19
Pandemic diphtheria
Philippines health access
Vaccines pertussis


Type Source Name
disease VO vaccine
drug DRUGBANK Tropicamide
disease MESH COVID-19 pandemic
disease VO immunization
disease MESH emergencies
disease MESH diphtheria
disease MESH tetanus
disease MESH pertussis
pathway KEGG Pertussis
disease VO combination vaccine
disease MESH polio
disease MESH hepatitis
disease VO frequency
disease MESH morbidity
disease VO effectiveness
disease VO organization
disease IDO cell
drug DRUGBANK Coenzyme M
disease MESH communicable diseases
disease MESH vaccine preventable diseases
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO country
disease VO vaccination
disease VO population
disease VO volume
disease VO time
disease VO dose
disease VO injection
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Aspartame
disease VO USA
disease MESH Death
disease VO effective
disease IDO production
disease VO vaccination coverage
disease VO report
drug DRUGBANK Rotavirus Vaccine
disease VO Rotavirus vaccine
disease VO organ
disease VO Canada

Original Article

(Visited 1 times, 1 visits today)